ロード中...
Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer
Echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) fusion accounts for 3%-5% of non-small cell lung cancer (NSCLC) patients. With the in-depth study of the EML4-ALK driver gene, ALK inhibitors represented by crizotinib have been gradually developed and applied in...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Chinês |
| 出版事項: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2020-11-01
|
| シリーズ: | Chinese Journal of Lung Cancer |
| 主題: | |
| オンライン･アクセス: | http://dx.doi.org/10.3779/j.issn.1009-3419.2020.101.44 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|